mbiomics

Executive Summary

mbiomics is a German biotechnology company founded in 2017 that develops rationally selected, defined microbial consortia as microbiome-based therapeutics. The company's platform leverages the immunological and metabolic potential of the gut microbiome to restore healthy microbial ecosystems, aiming to treat severe and chronic diseases such as inflammatory bowel disease and metabolic disorders. By precisely engineering bacterial communities, mbiomics seeks to match the efficacy of fecal microbiota transplantation while delivering superior safety and specificity. Despite limited public information on funding and pipeline status, the company's approach addresses a critical unmet need in microbiome medicine, where most therapeutic candidates are still in early clinical stages. mbiomics operates in the competitive microbiome therapeutics landscape, with key players like Seres Therapeutics and Vedanta Biosciences. The company's success will depend on advancing its lead candidates into clinical trials, securing partnerships, and demonstrating robust preclinical data.

Upcoming Catalysts (preview)

• TBDSeries A or B financing round60% success
• TBDIND filing for lead therapeutic candidate40% success
• TBDPublication of preclinical efficacy data in peer-reviewed journal70% success